Results 211 to 220 of about 22,351 (243)

Fingolimod

Reactions Weekly, 2020
  +9 more sources

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Multiple Sclerosis
Background: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking. Objectives: To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing ...
I. Roos, S. Sharmin, C. Malpas, S. Ozakbas, J. Lechner-Scott, S. Hodgkinson, R. Alroughani, S. Eichau Madueño, C. Boz, A. van der Walt, H. Butzkueven, K. Buzzard, O. Skibina, M. Foschi, F. Grand'Maison, N. John, P. Grammond, M. Terzi, J. Prevost, M. Barnett, G. Laureys, Liesbeth Van Hijfte, José Luis Sanchez-Menoyo, Y. Blanco, Jiwon Oh, P. McCombe, C. Ramo Tello, A. Soysal, A. Prat, P. Duquette, B. Yamout, S. Khoury, V. van Pesch, Richard Macdonell, M. José Sá, M. Slee, J. Kuhle, Davide Maimone, D. Spitaleri, Barbara Willekens, A. A. Asmi, E. Tallantyre, Neil Robertson, Alasdair J Coles, J. W. L Brown, T. Kalincik   +45 more
semanticscholar   +1 more source

Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark

Multiple Sclerosis
Background: Fingolimod may be associated with risk of developing cardiovascular disease (CVD). Studies including reference groups and long follow-up are scarce.
Elisabeth Framke, L. Thygesen, M. Malmborg, M. Schou, F. Sellebjerg, M. Magyari   +5 more
semanticscholar   +1 more source

Fingolimod

Reactions Weekly, 2017
  +8 more sources

Fingolimod

Reactions Weekly, 2021
  +7 more sources

Fingolimod

Reactions Weekly, 2019
  +8 more sources

Fingolimod

Reactions Weekly, 2015
  +7 more sources

Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells.

Toxicology Letters, 2018
Sphingolipids are critical regulators of tumor microenvironments and play an important role in estrogen-dependent cancers. Estrogen and estrogen metabolites were found to be involved in prostate cancer.
R. Allam, A. M. Al-Abd, A. Khedr, O. Sharaf, S. M. Nofal, A. Khalifa, H. Mosli, A. Abdel-Naim   +7 more
semanticscholar   +1 more source

The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis

Neurological Sciences, 2023
C. Boz, S. Ozakbas, M. Terzi, R. Karabudak, S. Sevim, R. Turkoglu, A. Soysal, B. P. Balci, H. Efendı, Ö. F. Turan, Nur Yüceyar, M. Yetkin, S. Z. Karahan, M. Demirkıran, S. Guler, K. Ağan, N. Kıylıoğlu, C. Baba, A. Tuncer, Mesrure Köseoğlu   +19 more
semanticscholar   +1 more source

Fingolimod

Reactions Weekly, 2016
  +5 more sources